Meplazumab
Based on 1 Customer Validation
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.70%
- Masse moléculaire:144.86 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
Basigin/CD147
Meplazumab significantly inhibits SARS-CoV-2 infection in vitro, with measurable cytopathic effect blocking (IC50 = 24.86 μg/mL), viral titer suppression (IC50 = 15.16 μg/mL)[1].
Meplazumab (72 h) significantly inhibits SARS-CoV-2 pseudovirus infection of activated human CD4+ and CD8+ T cells[2].
Meplazumab (100 μg/mL; 2 h) internalizes into NCI-H460 non-small cell lung cancer cells at 37 °C and traffics to lysosomes, while remaining primarily on the cell surface at 4 °C[3].
Meplazumab (10 μg/mL; 2 h) does not disrupt microtubule organization, centrosome separation, or chromosome alignment in mitotic NCI-H460 non-small cell lung cancer cells[3].
Meplazumab (72 h) does not exert significant antiproliferative activity in NCI-H460, NCI-H226, NCI-H520, A549, A549 CD147-knock down, or MRC-5 cells[3].
Meplazumab binds to purified CD147 antigen with high affinity, with an equilibrium dissociation constant of 0.47 nM[3].
Meplazumab (conjugated with DM1) induces G2/M phase cell cycle arrest and exerts antiproliferative activity in non-small cell lung cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H460 non-small cell lung cancer cells
-
Concentration:100 μg/mL
-
Incubation Time:2 h
-
Result:Was mainly detected on the cell surface with minimal internalization at 4 °C.
Showed intracellular co-localization with lysosomes, indicating internalization and trafficking to lysosomes at 37 °C.
Meplazumab (10 mg/kg; i.v.; twice weekly; 4 weeks) achieves 47.39% tumor volume inhibition and 48.80% tumor weight inhibition in NCI-H226 NSCLC xenograft nude mice with stable body weight[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice with A549 NSCLC xenograft[3]
-
Dosage:32 mg/kg
-
Administration:I.v.; twice weekly; 4 weeks
-
Result:Achieved a relative tumor volume inhibition rate (IRTV) of 48.87% and a relative tumor weight inhibition rate (IRTW) of 46.28%.
Reached a final average tumor volume of 326.36 ± 185.40 mm3 and final average tumor weight of 0.33 ± 0.18 g.
Showed no significant body weight difference compared to PBS controls, with body weight increasing by the end of the observation period.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 144.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Meplazumab]
-
Synonyms
HcHAb18
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Bian H, et al. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Transduct Target Ther. 2021;6(1):194. Published 2021 May 17. [Content Brief]
[2]. Wang K, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5(1):283. Published 2020 Dec 4. [Content Brief]
[3]. Huhe M, et al. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem Biophys Res Commun. 2019;513(4):1083-1091. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Meplazumab Related Classifications
HY-P991501 Related Classifications
Powered by Bioz